Skip to main content

Infectious Disease Dynamics

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
Search

Search form

  • Who we are
    • People
    • Collaborators
  • Projects
    • Cholera Dynamics
      • Data
    • COVID-19
    • Cross-Sectional Incidence Testing
    • Emerging Diseases
    • Fluscape
    • HIV Dynamics
    • Healthcare Epidemiology
    • Impetus
    • Measles & Rubella
    • Phylogenetic Study Design
  • Publications
  • Updates
  • Search
  • Home
  • Projects
  • Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

Cross-Sectional Incidence Testing

The capacity to accurately estimate incidence of HIV and HCV from cross sectional surveys is critical to the determining the current state of the epidemic and assessing the impact of population level interventions. These methodologies are used for country level incidence estimates, such as the Population-based HIV Impact Assessment (currently being performed in 15 countries receiving PEPFAR funding), large intervention trials, and at an individual level (for all newly diagnosed persons in the UK).

Using biomarkers associated with recent infection, we have developed and validated testing algorithms to generate point estimates of incidence and incidence differences between paired surveys.  Both serologic (properties of the antibody response) and nucleic acid (viral diversity) have been exploited for this purpose.

Publications

Inter-laboratory assessment of a prototype multiplex kit for determination of recent HIV-1 infection.
Curtis KA, Longosz AF, Kennedy MS, Keating S, Heitman J, Laeyendecker O, Owen SM.
PLoS One, 2013: 8(10): 77765, 10.1371/journal.pone.0077765
Cross-sectional HIV incidence estimation in HIV prevention research.
Brookmeyer R, Laeyendecker O, Donnell D, Eshleman SH.
J Acquir Immune Defic Syndr, 2013: 63 Supplement 2: S233-9, 10.1097/QAI.0b013e3182986fdf
Estimation of HIV incidence in a large, community-based, randomized clinical trial: NIMH project accept (HIV Prevention Trials Network 043).
Laeyendecker O, Piwowar-Manning E, Fiamma A, Kulich M, Donnell D, Bassuk D, Mullis CE, Chin C, Swanson P, Hackett J Jr, Clarke W, Marzinke M, Szekeres G, Gray G, Richter L, Alexandre MW, Chariyalertsak S, Chingono A, Celentano DD, Morin SF, Sweat M, Coates T, Eshleman SH.
PLoS One, 2013: 8(7): e68349, 10.1371/journal.pone.0068349
Differential specificity of HIV incidence assays in HIV subtypes A and D-infected individuals from Rakai, Uganda.
Mullis CE, Munshaw S, Grabowski MK, Eshleman SH, Serwadda D, Brookmeyer R, Nalugoda F, Kigozi G, Kagaayi J, Tobian AA, Wawer M, Gray RH, Quinn TC, Laeyendecker O.
AIDS Res Hum Retroviruses, 2013: 29(8): 1146-50, 10.1089/AID.2012.0105
Antibody maturation and viral diversification in HIV-infected women.
James MM, Laeyendecker O, Sun J, Hoover DR, Mullis CE, Cousins MM, Coates T, Moore RD, Kelen GD, Fowler MG, Kumwenda JJ, Mofenson LM, Kumwenda NI, Taha TE, Eshleman SH.
PLoS One, 2013: 8(2): e57350, 10.1371/journal.pone.0057350
Effect of natural and ARV-induced viral suppression and viral breakthrough on anti-HIV antibody proportion and avidity in patients with HIV-1 subtype B infection.
Wendel SK, Mullis CE, Eshleman SH, Blankson JN, Moore RD, Keruly JC, Brookmeyer R, Quinn TC, Laeyendecker O.
PLoS One, 2013: 8(2): e55525, 10.1371/journal.pone.0055525
Estimation of HIV incidence using multiple biomarkers.
Brookmeyer R, Konikoff J, Laeyendecker O, Eshleman SH.
Am J Epidemiol, 2013: 77(3): 264-72, 10.1093/aje/kws436
Lower-sensitivity and avidity modifications of the vitros anti-HIV 1+2 assay for detection of recent HIV infections and incidence estimation.
Keating SM1, Hanson D, Lebedeva M, Laeyendecker O, Ali-Napo NL, Owen SM, Stramer SL, Moore RD, Norris PJ, Busch MP.
J Clin Microbiol, 2012: 50(12): 3968-76, 10.1128/JCM.01454-12

Pages

  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • next ›

Contact

Tel: xxx-xxx-xxxx

Email: iddynam [at] jhu.edu

Infectious Disease Dynamics Group
c/o Amy Wesolowski
Johns Hopkins Bloomberg School of Public Health
615 North Wolfe Street, E6516
Baltimore MD 21205

Social

Twitter
 
  • Disclaimer & Privacy
  • Sitemap
© 2022 Infectious Disease Dynamics
Website by Manta Ray Media